WithdrawnPhase 4NCT02779257

Pasireotide Treatment for Neuroendocrine Tumor

Studying Neuroendocrine neoplasm of pancreas

Last synced from ClinicalTrials.gov April 1, 2026

ℹ

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.

Report missing data

Key facts

Sponsor: University of Maryland, Baltimore
Principal Investigator: Kashif M Munir, MD
University of Maryland, Baltimore
Intervention: Pasireotide(drug)
Eligibility: 18-75 years · MALE
Timeline: 2016 – 2016

Collaborators

Novartis

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT02779257 on ClinicalTrials.gov

Other trials for Neuroendocrine neoplasm of pancreas

Additional recruiting or active studies for the same condition.

RECRUITINGNANCT06246630
In Vitro Organoid Drug Sensitivity-Guided Treatment for Advanced Pancreatic Neuroendocrine Tumor
Ruijin Hospital
RECRUITINGNANCT05243082
Endoscopic Ultrasound Guided Radio Frequency Ablation of Pancreatic Neuroendocrine Neoplasms
Oslo University Hospital

See all trials for Neuroendocrine neoplasm of pancreas →

← Back to all trials